Bayer has announced that it has extended its research partnership with the Broad Institute by five years, bringing to fifteen years a collaboration that began in 2013 in the field of human genomics applied to cardiovascular disease.
This expanded agreement aims to strengthen the identification of precision therapeutic targets in cardiology and accelerate the validation of discoveries through a human cardiomyocyte platform.
The joint research focuses in particular on dilated cardiomyopathy (DCM), a condition characterized by dilation of the heart chambers leading to heart failure.
The collaboration has already led to several publications and the entry into Phase I, in May 2025, of a selective GIRK4 inhibitor for the potential treatment of atrial fibrillation.
Bayer says the partnership is part of its strategy to develop innovative therapies in cardiovascular health, an area of high medical need.
Copyright (c) 2025 CercleFinance.com. All rights reserved.
Bayer AG is one of the world's leaders in designing, producing, and marketing pharmaceutical products and agrochemicals. Net sales are distributed by product family as follows:
- agrochemicals (47.5%): herbicides, fungicides, insecticides, etc.;
- pharmaceutical products (39.1%): intended for the prevention and treatment of cardiovascular and respiratory diseases, diabetes, nervous system disorders, etc.;
- OTC products and nutritional supplements (12.7%);
- other (0.7%).
Net sales are distributed geographically as follows: Germany (5.7%), Switzerland (1%), Europe-Middle East-Africa (22.9%), United States (33.1%), North America (3.6%), China (7.6%), Asia-Pacific (8.9%), Brazil (9.6%), and Latin America (7.6%).
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
